KR20120005195A - Hair loss prevention and hair growth promoting composition comprising ginseng fruit extract - Google Patents
Hair loss prevention and hair growth promoting composition comprising ginseng fruit extract Download PDFInfo
- Publication number
- KR20120005195A KR20120005195A KR1020100065809A KR20100065809A KR20120005195A KR 20120005195 A KR20120005195 A KR 20120005195A KR 1020100065809 A KR1020100065809 A KR 1020100065809A KR 20100065809 A KR20100065809 A KR 20100065809A KR 20120005195 A KR20120005195 A KR 20120005195A
- Authority
- KR
- South Korea
- Prior art keywords
- hair
- composition
- ginseng fruit
- ginseng
- fruit extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 110
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 102
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 100
- 239000000284 extract Substances 0.000 title claims abstract description 82
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 78
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 230000003779 hair growth Effects 0.000 title claims abstract description 33
- 230000001737 promoting effect Effects 0.000 title claims abstract description 22
- 230000003658 preventing hair loss Effects 0.000 title claims abstract description 20
- 241000208340 Araliaceae Species 0.000 title claims abstract 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 210000004209 hair Anatomy 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 18
- 229930182494 ginsenoside Natural products 0.000 claims description 15
- 229940089161 ginsenoside Drugs 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 230000002500 effect on skin Effects 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 9
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims description 8
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 239000002453 shampoo Substances 0.000 claims description 3
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- 239000000118 hair dye Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 21
- 210000003491 skin Anatomy 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract description 9
- 230000008929 regeneration Effects 0.000 abstract description 2
- 238000011069 regeneration method Methods 0.000 abstract description 2
- 210000004927 skin cell Anatomy 0.000 abstract description 2
- 230000000638 stimulation Effects 0.000 abstract description 2
- 240000004371 Panax ginseng Species 0.000 description 97
- 201000004384 Alopecia Diseases 0.000 description 23
- 235000019441 ethanol Nutrition 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000000605 extraction Methods 0.000 description 15
- 230000003676 hair loss Effects 0.000 description 15
- 208000024963 hair loss Diseases 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- 235000002789 Panax ginseng Nutrition 0.000 description 11
- 210000003780 hair follicle Anatomy 0.000 description 10
- 231100000360 alopecia Toxicity 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000306 component Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000020710 ginseng extract Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical group C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000003024 Diffuse alopecia Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000180649 Panax notoginseng Species 0.000 description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 2
- 230000003659 hair regrowth Effects 0.000 description 2
- 229940107632 korean ginseng root extract Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical group C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- -1 saponin quaternary ammonium compounds Chemical class 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 201000001297 telogen effluvium Diseases 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- FBFNMTGUOBUGFQ-UHFFFAOYSA-M 2-(2,5-diphenyltetrazol-1-ium-1-yl)-4,5-dimethyl-1,3-thiazole;bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=C(C=2C=CC=CC=2)N=NN1C1=CC=CC=C1 FBFNMTGUOBUGFQ-UHFFFAOYSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 241000168720 Panax japonicus Species 0.000 description 1
- 235000003174 Panax japonicus Nutrition 0.000 description 1
- 241001527087 Panax vietnamensis Species 0.000 description 1
- 235000017726 Panax vietnamensis Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000034557 congenital alopecia Diseases 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229940107889 rogaine Drugs 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000004018 waxing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 인삼 열매 추출물을 유효성분으로 포함하는 탈모 방지 및 모발 성장 촉진용 조성물에 관한 것이다. 상기 인삼 열매 추출물은 피부에 대한 자극이 없고, 탁월한 피부세포 재생 효과로 인해 발모 촉진, 탈모 예방 및 치료 개선을 통해 탈모 방지 및 모발 성장 촉진용 조성물을 제공하는 효과가 있다. The present invention relates to a hair loss prevention and hair growth promoting composition comprising a ginseng fruit extract as an active ingredient. The ginseng fruit extract has no stimulation to the skin, and has an effect of providing a composition for preventing hair loss and promoting hair growth through hair growth promotion, hair loss prevention and treatment improvement due to excellent skin cell regeneration effect.
Description
본 발명은 인삼 열매 추출물을 유효성분으로 포함하는 탈모 방지 및 모발 성장 촉진용 조성물에 관한 것이다.
The present invention relates to a hair loss prevention and hair growth promoting composition comprising a ginseng fruit extract as an active ingredient.
최근 국내는 물론 세계적으로, 탈모가 시작되는 연령이 낮아지고 있다. 또한, 인간 수명이 연장되면서 일생 동안 탈모로 인한 고충을 겪는 인구가 점점 늘어나고 있는 실정이다. 이런 추이에 맞춰 탈모에 대한 관심이 고조되고 있다.In recent years, both domestically and globally, the age at which hair loss begins has decreased. In addition, as the human lifespan is extended, more and more people are suffering from hair loss during their lifetime. In line with this trend, interest in hair loss is increasing.
널리 알려진 탈모의 원인으로, 남성 호르몬인 테스토스테론(testosterone)의 과다 분비, 모낭(hair follicle)의 혈류량 저하, 모근세포의 형질에 의한 유전적 원인, 약물에 의한 부작용, 세균 번식이나 피지 분비 과다에 의한 두피 이상, 나이, 스트레스 등이 있다. 그러나 탈모에 대한 정확한 원인은 아직까지 명확하게 규명되어 있지 않다.Known causes of hair loss include excessive secretion of the testosterone, a testosterone, decreased blood flow to hair follicles, genetic causes of hair follicle traits, side effects from drugs, overgrowth of bacteria and sebum secretion. Scalp abnormalities, age, and stress. However, the exact cause of hair loss is not yet clearly identified.
인체의 모발은 약 130만개 이상, 두발은 10만개 이상이다. 이들 모발은 생장기(anagen), 퇴행기(catagen), 휴지기(telogen)의 3단계 주기를 거치며, 각 모발은 독립적인 주기로 활동하며 진행된다. Human hair is about 1.3 million or more hair, 100,000 or more hair. These hairs go through three stages: anagen, catagen, and telogen, with each hair working in an independent cycle.
탈모는 머리카락이나 털이 어떤 원인에 의하여 정상보다 적거나 없는 상태를 의미하며, 크게 모발이 휴지기 상태에서 빠지는 일반적인 탈모 현상(휴지기 탈모, telogen effluvium)과 비정상적인 탈모 현상인 생장기 탈모 현상(anagen effluvium)으로 구별할 수 있다. 이 때 후자를 일반적으로 탈모라 일컫는다. Hair loss refers to a condition in which hair or hair is less or less than normal due to some cause, and is classified into general hair loss phenomenon (telogen effluvium) in which hair falls out of a resting state and anagen effluvium, which is abnormal hair loss. can do. The latter is generally called hair loss.
탈모(또는 탈모 질환)는 형태, 증상 또는 원인 등에 따라, 원형 탈모증(Alopecia Areata), 유전성 안드로겐 탈모증(Androgenetic Alopecia), 휴지기 탈모증(Telogen Effluvium), 외상성, 발모벽(Trichoti lomania), 압박성(Pressure Alopecia)등의 생장기 탈모증, 비강성, 매독성(Alopecia syphlltiac), 지루 탈모증(Alopecia seborrhecia), 증후성, 반흔성, 선천성 탈모증 등으로 분류되고 있다.Alopecia (or alopecia disorders) may include alopecia areata, hereditary androgen alopecia, telogen effluvium, traumatic, tritoti lomania, and pressure, depending on the form, symptoms, or causes Alopecia is classified as growing alopecia, nasal stiffness, alopecia syphlltiac, seborrheic alopecia (Alopecia seborrhecia), symptomatic, scarring, congenital alopecia.
탈모 치료 방법에는 모낭 세포이식 수술법 및 약물 치료법이 있다. 수술법은 간단하지 않고 비용 부담이 있으며, 약물 치료법은 약물 부작용, 치료 기간의 장기화 등의 문제점이 있다. Hair loss treatment methods include hair follicle transplantation and drug treatment. Surgical methods are not simple and costly, and drug treatments have problems such as drug side effects and prolonged treatment period.
그밖에 여성호르몬을 이용한 사례가 있으나, 효과가 뛰어나지 못할 뿐만 아니라 피부 염증 발생, 호르몬 투여에 의한 부작용 발생 등으로 인하여 현재는 사용이 중단되고 있다. In addition, there are cases of using female hormones, but their effectiveness is not only excellent, but due to skin inflammation, side effects caused by hormone administration, etc. are currently discontinued.
발모제의 종류로는, 미국 업존(Upjhon)사의 미녹시딜(minoxidil), 이태리 크리노스(Crinos)사의 트리코사카라이드(trichosaccharide) 등을 주성분으로 하는 제제가 사용되고 있으나, 뚜렷한 효과의 부재 및 부작용 문제가 대두되고 있다. As the type of hair regrowth, preparations based on Minoxidil, Trichosaccharide from Crinos, Italy, etc. are used, but there are no obvious effects and side effects. have.
또 머크사(Merk)는 모낭에서 남성호르몬 테스토스테론 대사에 작용하는 효소인 5α-환원효소(5α-reductase)의 활성을 억제시키는 피나스테라이드(finasteride)가 탈모에 유효하다고 하였으나, 이는 반드시 지속적인 투여가 필요하며, 우울증을 유발할 수 있다는 문제점이 있다.In addition, Merck said that finasteride, which inhibits the activity of 5α-reductase, an enzyme that acts on male hormone testosterone metabolism in hair follicles, is effective for hair loss, it must be administered continuously. There is a problem that can cause depression.
그 밖에 크레시나(crescina)와 로게인(rogaine)은 탈모 질환이 완전히 진행되기 전인 정상 두피에 모근이 살아있는 경우에만 사용된다. 이처럼 종래의 여러 종류의 발모제는 일반적으로 두피의 혈액 촉진과 모근의 영양공급을 목적으로 하여 모발 성장에 도움을 주려하나, 이 역시 독성과 부작용이 심하고 그 효과 또한 미흡한 것이 현 실정이다. In addition, crescina and rogaine are used only if the hair roots are alive in normal scalp before the hair loss disease is fully developed. As described above, various types of hair regrowth are generally intended to help hair growth for the purpose of promoting blood pressure and nourishing hair roots, but these are also toxic and side effects are severe and the effect is also insufficient.
그리하여 천연물 소재를 이용하여 탈모 방지 또는 모발 성장 촉진 효과를 목적으로 하는 향장 제품, 샴푸, 헤어로션, 헤어크림, 헤어 젤 등과 같은 기능제품에 대한 개발 및 연구가 국내에서 활발하게 진행 중이다. Therefore, the development and research on functional products such as cosmetic products, shampoos, hair lotions, hair creams, hair gels, etc. aiming at preventing hair loss or promoting hair growth using natural materials are actively underway in Korea.
대표적으로, 천연물 소재로 각광받고 있는 인삼 중 고려인삼(Panax ginseng)은 신농본초경에서 상품(上品)으로 수록되어 독성이 적어 안전하고, 맛이 달고 약간 따뜻하며, 상·중초, 즉 폐와 비에 작용하는 대보원기요약으로 한국의 대표적인 특산물이다. Among the ginsengs that are spotlighted as natural products, Panax ginseng is listed as a commodity in new agricultural plants, so it is less toxic and safe, sweet and slightly warm. It is the representative special product of Korea.
고려인삼의 생리활성 물질은 항당뇨 효과를 갖는 진세노사이드 Rb2를 비롯한 30 여종의 인삼 사포닌(saponins)과 항암 효과를 갖는 폴리아세틸렌, 항산화 작용을 갖는 페놀계 화합물, 방사선 방어 작용을 갖는 인삼 단백질 및 면역조절 작용을 갖는 산성 다당체 등을 함유하고 있다.Physiologically active substances of Korean ginseng include 30 kinds of ginseng saponins including ginsenoside Rb 2 with antidiabetic effect, polyacetylene with anticancer effect, phenolic compounds with antioxidant action, and ginseng protein with radiation defense action. And acidic polysaccharides having an immunomodulatory effect.
고려인삼의 주된 약리성분으로 알려진 인삼 사포닌은 진세노사이드라 불린다. 고려인삼에 함유되어 있는 인삼 사포닌은 30 여종으로, 서양삼(Panax quinquefolium)의 14 종과 삼칠삼(Panax notoginseng)의 15 종에 비해 월등히 많다. Ginseng saponin, known as the main pharmacological component of Korean ginseng, is called ginsenoside. Korean ginseng contains about 30 kinds of ginseng saponins, much more than 14 kinds of Panax quinquefolium and 15 kinds of Panax notoginseng .
진세노사이드는 프로토파낙사디올(protopanaxadiol) 그룹과 프로토파낙사트리올(protopanaxatriol) 그룹으로 크게 나누어진다. 프로토파낙사디올 그룹의 주요 성분은 진세노사이드 Rb1이고, 이는 중추신경 억제작용을 나타내며, 프로토파낙사트리올 그룹의 주요 성분은 진세노사이드 Rg1으로 중추신경 흥분작용을 나타낸다. 이들은 고려인삼의 어댑토젠(adaptogen, 강장제) 활성에 주요하게 기여하는 성분으로 알려져 있다. Ginsenosides are largely divided into the protopanaxadiol group and the protopanaxatriol group. The main component of the ProtoPanaxadiol group is ginsenoside Rb 1 , which represents the central nervous system inhibitory activity, and the main component of the ProtoPanaxatriol group is the ginsenoside Rg 1 , which represents central nervous system excitability. They are known to be the major contributors to the activity of adaptogen (adaptogen) of Korean ginseng.
인삼의 탈모 방지 또는 발모 촉진 작용에 대한 연구 결과로, 가수분해된 인삼사포닌 4급 암모늄 화합물이 모발 컨디셔닝 효과가 있다고 보고된 바 있고(Kim et al. Int J Cosmet Sci ., 11(5), 203-220, 1989), 홍삼과 진세노사이드 Rb1와 Rg3가 발모촉진작용에 대해 보고된바 있다(Matsuda et al., Phytother Res. 17(7), 797-800, 2003).Studies on the prevention of hair loss or promoting hair growth of ginseng have been reported to have a hair conditioning effect of hydrolyzed ginseng saponin quaternary ammonium compounds (Kim et al . Int J Cosmet Sci . , 11 (5), 203-220, 1989) Red ginseng and ginsenosides Rb 1 and Rg 3 have been reported for hair growth promoting activity (Matsuda et al ., Phytother Res. 17 (7), 797-800 , 2003).
그러나 인삼 열매(과육)속 유효 성분이 탈모 방지 또는 모발 성장 촉진용 조성물로 사용될 수 있다고 알려진 바는 없었다.However, it is not known that ginseng fruit (pulp) active ingredient can be used as a composition for preventing hair loss or promoting hair growth.
이에 본 발명자는 인삼 열매를 이용한 기능성 제품을 연구하던 중, 인삼 열매를 용매로 추출할 경우 진세노사이드 Re의 함량이 높은 조성물 얻게 되고, 이렇게 얻은 조성물이 탈모 방지 및 모발 성장 촉진에 효과적이라는 것을 알게 되어 본 발명을 완성하기에 이르렀다.
Thus, while the present inventors are studying a functional product using ginseng fruit, when the ginseng fruit is extracted with a solvent, a high content of ginsenoside Re is obtained, and thus the composition obtained is effective in preventing hair loss and promoting hair growth. Thus, the present invention has been completed.
본 발명의 목적은 합성 화학물질에 비해 안전성이 확보된 천연물인 인삼 열매 추출물을 포함하는 탈모 방지 및 모발 성장 촉진용 조성물을 제공하기 위한 것이다.It is an object of the present invention to provide a composition for preventing hair loss and promoting hair growth, including ginseng fruit extract which is a safe natural product compared to synthetic chemicals.
본 발명의 다른 목적은 인삼 열매 추출물을 유효성분으로 포함하는 약학용 조성물 및 화장료 조성물을 제공하기 위한 것이다.
Another object of the present invention is to provide a pharmaceutical composition and cosmetic composition comprising a ginseng fruit extract as an active ingredient.
상기와 같은 목적을 달성하기 위하여, 본 발명은 인삼 열매 추출물을 유효성분으로 포함하는 탈모 방지 및 모발 성장 촉진용 조성물을 제공한다. In order to achieve the above object, the present invention provides a composition for preventing hair loss and promoting hair growth comprising ginseng fruit extract as an active ingredient.
상기 인삼 열매 추출물은, 인삼 열매 추출물 내 총진세노사이드 중량에 대하여, 진세노사이드 Re를 1 내지 70 중량%로 포함할 수 있다. The ginseng fruit extract may include 1 to 70% by weight of ginsenosides Re based on the total ginsenoside weight in the ginseng fruit extract.
상기 인삼 열매 추출물은 인삼의 열매, 인삼화, 인삼 줄기 및 인삼잎으로 이루어진 군으로부터 선택되는 하나 이상으로부터 추출한 추출물일 수 있다. The ginseng fruit extract may be an extract extracted from one or more selected from the group consisting of ginseng fruit, ginseng flower, ginseng stem and ginseng leaf.
상기 추출물을 제조하는 방법은 초음파 추출법, 여과법, 열수추출법 및 환류추출법 등 당업계의 통상적인 추출방법을 사용할 수 있다.Method for preparing the extract may be used in the conventional extraction methods such as ultrasonic extraction, filtration, hot water extraction and reflux extraction method.
구체적으로 인삼 열매 추출물이란, 고려인삼(Panax ginseng), 서양삼(Panax quinquefolium), 삼칠삼(Panax notoginseng), 죽절삼(Panax japonicum) 또는 파낙스 베트남엔시스(Panax vietnamensis)와 같은 파낙스(Panax) 속 식물의 지상부 생약, 예를 들어, 인삼열매(과육), 인삼화(화뢰), 인삼 줄기, 인삼 잎의 추출물을 포함하며, 이들을 가공 처리한 경우도 이용될 수 있다. Specifically, the ginseng fruit extract refers to a plant of the genus Panax such as Panax ginseng , Panax quinquefolium , Panax notoginseng , Panax japonicum or Panax vietnamensis . The above-mentioned herbal medicine, for example, ginseng fruit (pulp), ginseng (flower bud), ginseng stem, extracts of ginseng leaves, and may be used in the case of processing them.
이때의 가공 처리는 필요에 따라서 공지된 방법에 의한 추출일 수 있다. 가공 인삼 추출물은 인삼류를 물, 저급알콜(메탄올, 에탄올 등), 저급케톤(아세톤, 메틸에틸케톤 등), 초임계유체 또는 이들의 혼합용매를 이용하여 추출한 후, 농축시키거나 또는 농축된 액을 건조시킴으로써 용매를 제거하여 건조된 분말상의 가공인삼 추출물, 즉 인삼을 연조 또는 건조 엑스의 형태로 제조될 수 있다. The processing at this time may be extraction by a known method as necessary. Processed ginseng extract is extracted with water, lower alcohol (methanol, ethanol, etc.), lower ketone (acetone, methyl ethyl ketone, etc.), supercritical fluid, or a mixed solvent thereof, and then concentrated or concentrated liquid. The dried ginseng extract, ie, ginseng, may be prepared in the form of a soft or dry extract by removing the solvent by drying.
상기 추출용매는 물, C1∼C4 의 알콜, n-헥산, 에틸 아세테이트 및 이들의 혼합용매로 이루어진 군으로부터 선택될 수 있다. 아울러, 상기 추출용매는 에탄올 농도가 70 내지 95%인 에탄올 수용액 또는 메탄올 수용액을 이용하는 것이 바람직하다. The extractant may be selected from the group consisting of water, C 1 -C 4 alcohols, n-hexane, ethyl acetate, and mixed solvents thereof. In addition, the extraction solvent is preferably used an aqueous ethanol or methanol aqueous solution having an ethanol concentration of 70 to 95%.
상기 에탄올 수용액의 에탄올 농도가 70% 미만인 경우 인삼 열매 속 인체 생리 활성을 갖는 유효성분이 적게 추출될 수 있고, 95% 초과인 경우 알콜의 자극성으로 인하여 피부에 부작용을 유발하기에, 상기 범위의 에탄올 수용액을 사용하는 것이 바람직하다. 그리고 상기 메탄올 수용액은 메탄올 농도가 100%인 것을 사용할 수 있다.When the ethanol concentration of the ethanol aqueous solution is less than 70%, less active ingredient having a human physiological activity in the ginseng fruit can be extracted, and when the ethanol concentration is greater than 95%, causing side effects to the skin due to the stimulation of alcohol, ethanol aqueous solution of the above range Preference is given to using. In addition, the methanol aqueous solution may be used having a methanol concentration of 100%.
상기 에탄올 수용액 등을 이용한 추출은 40 내지 120℃에서 0.5 내지 4 시간 동안 가열 추출 하는 것이 바람직하다. Extraction using the ethanol aqueous solution and the like is preferably extracted by heating at 40 to 120 ℃ for 0.5 to 4 hours.
상기 가열 추출 온도가 40℃ 미만인 경우 인삼 열매 속 진세노사이드 Re 등의 유효성분 추출 함량이 적어질 수 있고, 120℃ 초과인 경우 진세노사이드 Re의 추출 효율이 더 이상 증가하지 않기에 경제적인 효율을 고려하여, 상기 범위 내에서 가열 추출하는 것이 바람직하다.If the heating extraction temperature is less than 40 ℃ extraction content of the active ingredient, such as ginsenoside Re in ginseng fruit may be less, and when the extraction temperature is higher than 120 ℃ ginsenoside Re extraction efficiency does not increase any more economical efficiency In consideration of this, it is preferable to extract by heating within the above range.
상기 가열시간이 0.5 시간 미만인 경우 인삼 열매 속 진세노사이드 Re 등의 유효성분 추출 함량이 적어 질 수 있고, 4 시간 초과인 경우 진세노사이드 Re의 추출 효율이 더 이상 증가하지 않기에 경제적인 효율을 고려하여, 상기 범위 내에서 가열 추출하는 것이 바람직하다.If the heating time is less than 0.5 hours, the extraction content of the active ingredient, such as ginsenoside Re in the ginseng fruit may be reduced, and if more than 4 hours, the extraction efficiency of ginsenoside Re does not increase any more economically. In consideration, it is preferable to heat-extract within the said range.
그리고 에탄올 수용액 등을 이용한 추출을 실온에서 수행하는 경우, 5일 내지 10일 동안, 바람직하게는 약 7일 동안 수행될 수 있다. 또한, 필요에 따라 차광 및/또는 가온(예를 들어, 온침) 조건하에서 수행될 수도 있다. And when the extraction using an ethanol aqueous solution or the like is performed at room temperature, it may be performed for 5 to 10 days, preferably about 7 days. It may also be carried out under shading and / or warming (eg warming) conditions as needed.
특히, 인삼 열매(과육)에 알코올을 5∼ 15배량 가하여 0.5∼4 시간, 40∼120 ℃에서 가열 추출하면 진세노사이드 Re가 1∼ 70 중량%로 함유된 추출물을 얻을 수 있다. 또한, 인삼열매(과육)에 증류수를 5∼15배량 가하여 0.5∼4 시간, 40 ∼120 ℃에서 가열 추출하면 진세노사이드 Re를 1∼70 중량%로 함유한 추출물을 얻을 수 있다.In particular, by adding 5 to 15 times the amount of alcohol to the ginseng fruit (pulp), and extracted by heating at 40 to 120 ℃ for 0.5 to 4 hours, an extract containing 1 to 70% by weight of ginsenoside Re can be obtained. In addition, 5-15 times the amount of distilled water is added to the ginseng fruit (pulp) and extracted by heating at 40 to 120 ° C. for 0.5 to 4 hours to obtain an extract containing 1 to 70% by weight of ginsenoside Re.
상기 추출과정은 일회 또는 복수 회 수행할 수 있으며, 바람직하게는 약 3회 정도 반복 수행할 수 있다. 상기 혼합 추출액은 필요에 따라 통상의 방법, 예를 들어 20 내지 40℃에서 감압 농축하거나 감압 건조함으로써, 액상, 반고체상 또는 분말 형태로 얻을 수 있다.The extraction process may be performed once or plural times, preferably about three times. The mixed extract may be obtained in a liquid, semi-solid or powder form by a conventional method, for example, by concentrating under reduced pressure or drying under reduced pressure at 20 to 40 ° C. as necessary.
이러한 용매 추출법을 이용하는 경우 물로 끓여내는 열수 추출법에 비해 유효성분을 많이 추출할 수 있는 장점이 있다. 아울러, 인삼 열매 속 유효성분의 추출 함량을 높이기 위해 크로마토그래피 분획 공정을 추가로 수행할 수 있다.When using such a solvent extraction method there is an advantage that can extract a lot of active ingredients compared to the boiling water extraction method boiled with water. In addition, in order to increase the extraction content of the active ingredient in ginseng fruit, a chromatography fractionation process may be further performed.
상기 인삼 열매 추출물은 인간 모유두 세포 성장 촉진 효과가 있다. 또한 탁월한 피부세포 재생효과로 인해 발모 촉진, 탈모 예방 및 치료에 사용될 수 있다.The ginseng fruit extract has an effect of promoting the growth of human dermal papilla cells. In addition, due to excellent skin cell regeneration effect can be used to promote hair growth, prevent hair loss and treatment.
본 발명의 조성물은 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제 및 멸균 주사용액로 이루어지는 군으로부터 선택되는 제형을 가지는 약학용 조성물로 이용될 수 있다.The composition of the present invention can be used as a pharmaceutical composition having a formulation selected from the group consisting of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, external preparations and sterile injectable solutions.
보다 상세하게 본 발명의 조성물은 상기 인삼 열매 추출물 및 약학적으로 허용 가능한 담체를 포함하는 약학용 조성물 형태일 수 있다. 상기 약학 조성물은 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제 및 멸균 주사용액의 형태로 제제화될 수 있다. More specifically, the composition of the present invention may be in the form of a pharmaceutical composition comprising the ginseng fruit extract and a pharmaceutically acceptable carrier. The pharmaceutical composition may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, oral formulations, external preparations and sterile injectable solutions according to conventional methods.
상기 약학적으로 허용 가능한 담체는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 포함한다. The pharmaceutically acceptable carrier is lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like.
또한, 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 포함한다. 경구용 고형 제제는 정제, 환제, 산제, 과립제, 캡슐제 등을 포함하며, 이러한 고형제제는 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘 카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 포함할 수 있으며, 마그네슘 스테아레이트, 탈크 같은 윤활제 등을 포함할 수 있다. Also included are diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, and the like. Oral solid preparations include tablets, pills, powders, granules, capsules and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, sucrose or lactose. ), Gelatin, and the like, and may include a lubricant such as magnesium stearate, talc, and the like.
경구용 액상 제제는 현탁제, 내용액제, 유제, 시럽제 등을 포함하며, 물, 리퀴드 파라핀 등의 희석제, 습윤제, 감미제, 방향제, 보존제 등을 포함할 수 있다. 비경구용 제제는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제를 포함하며, 비수성 용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르류 등을 포함한다. Oral liquid preparations include suspensions, solvents, emulsions, syrups, and the like, and may include water, diluents such as liquid paraffin, wetting agents, sweeteners, fragrances, preservatives, and the like. Parenteral preparations include sterile aqueous solutions, non-aqueous solvents, suspending agents, emulsions, and lyophilized preparations. Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, and vegetable oils such as olive oil and ethyl oleate. Injectable esters such as the like and the like.
한편 상기 약학 조성물에 함유되는 인삼 열매 추출물의 투여량은 환자의 상태 및 체중, 질병의 정도, 약물 형태, 투여 경로 및 기간에 따라 다르지만, 경우에 따라 적절하게 선택될 수 있다. 예를 들면, 상기 인삼 열매 추출물은 1일 0.0001 내지 100 mg/kg으로, 바람직하게는 0.01 내지 100 mg/kg의 용량으로 투여할 수 있으며, 상기 투여는 하루에 한번 또는 수회 나누어 투여할 수도 있다. Meanwhile, the dosage of the ginseng fruit extract contained in the pharmaceutical composition varies depending on the condition and weight of the patient, the degree of the disease, the drug form, the route of administration and the duration, and may be appropriately selected in some cases. For example, the ginseng fruit extract may be administered at a dose of 0.0001 to 100 mg / kg, preferably 0.01 to 100 mg / kg, and the administration may be administered once or several times a day.
또한 상기 약학 조성물은 조성물 총 중량에 대하여 상기 인삼 열매 추출물을 0.001 내지 50 중량%로 포함할 수 있다. 상기 약학 조성물은 인간 등의 포유동물에 다양한 경로로, 예를 들면, 경구, 정맥, 근육, 또는 피하 주사에 의해 투여될 수 있다. In addition, the pharmaceutical composition may comprise 0.001 to 50% by weight of the ginseng fruit extract based on the total weight of the composition. The pharmaceutical compositions can be administered to mammals, such as humans, by various routes, for example by oral, intravenous, intramuscular, or subcutaneous injection.
그리고 본 발명의 조성물은 상기한 인삼 열매 추출물을 유효성분으로 포함하는 기능성 화장료 조성물 형태일 수 있다. 예를 들면, 유연화장수, 수렴화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 염모제, 샴푸 및 린스로 이루어지는 군으로부터 선택되는 제형을 가지는 화장료 조성물로 이용될 수 있다. 그리고 본 발명의 조성물은 통상의 클렌징액, 수렴액 및 보습액으로 희석하여 사용될 수 있으며, 화장료 조성물 분야에서 통상적으로 사용되는 안정화제, 용해화제, 비타민, 안료, 및 향료와 같은 통상적인 보조제를 포함할 수 있다. And the composition of the present invention It may be in the form of a functional cosmetic composition comprising the ginseng fruit extract as an active ingredient. For example, it may be used as a cosmetic composition having a formulation selected from the group consisting of softening cream, converging cream, nourishing cream, nourishing cream, massage cream, essence, hair dye, shampoo and rinse. And the composition of the present invention can be used diluted with a conventional cleansing liquid, astringent liquid and moisturizing liquid, and may include conventional auxiliaries such as stabilizers, solubilizers, vitamins, pigments, and fragrances commonly used in the cosmetic composition field. Can be.
상기 본 발명의 약학용 및 화장용 조성물은 상기 언급한 형태로 제한되지 않으며, 탈모 방지 및 모발 성장 용도라면 다양한 형태로 제조될 수 있다. 즉, 본 발명에 따른 인삼 열매 추출물은 각종 기능성 제품에 활용될 수 있다.
The pharmaceutical and cosmetic compositions of the present invention are not limited to the above-mentioned forms, and may be prepared in various forms as long as it is used for hair loss prevention and hair growth. That is, the ginseng fruit extract according to the present invention can be utilized in various functional products.
본 발명에 따란 인삼 추출물을 유효 성분으로 포함하는 조성물은, 피부에 대한 자극이 없으며, 탈모 방지 및 모발 성장 촉진 효과를 가진다.
The composition comprising the ginseng extract according to the present invention as an active ingredient, there is no irritation to the skin, and has the effect of preventing hair loss and promoting hair growth.
도 1은 한국 인삼 종자 추출물(KGS)의 진세노사이드 분석 결과를 나타낸 HPLC 크로마토그램이다(a: Rg1, b: Re, c: Rb1, d: Rc, e: Rb2, f: Rd).
도 2는 한국 인삼 열매 추출물(KGB)의 진세노사이드 분석 결과를 나타낸 HPLC 크로마토그램이다.
도 3은 인삼 열매 추출물이 인간 모유두세포(human hair dermal papilla cell, HHDPC)의 성장에 미치는 효과를 나타낸 그래프이다
도 4는 인삼 열매 추출물이 C57BL/6 마우스의 모발 생장에 미치는 효과를 나타낸 사진이다.
도 5는 인삼 열매 추출물이 C57BL/6 마우스의 모발 생장에 미치는 효과를 나타낸 모낭의 조직학적 단면도다.
도 6은 인삼 열매 추출물이 도포된 C57BL/6 마우스의 모발의 질량을 나타낸 그래프이다.1 is a HPLC chromatogram showing the results of ginsenoside analysis of Korean ginseng seed extract (KGS) (a: Rg1, b: Re, c: Rb1, d: Rc, e: Rb2, f: Rd).
Figure 2 is an HPLC chromatogram showing the results of ginsenoside analysis of Korean ginseng fruit extract (KGB).
3 is a graph showing the effect of ginseng fruit extract on the growth of human hair dermal papilla cells (HHDPC)
Figure 4 is a photograph showing the effect of ginseng fruit extract on the hair growth of C57BL / 6 mice.
5 is a histological cross-sectional view of hair follicles showing the effect of ginseng fruit extract on the hair growth of C57BL / 6 mice.
Figure 6 is a graph showing the mass of the hair of C57BL / 6 mice to which ginseng fruit extract is applied.
이하에서는, 본 발명의 구성을 실시예를 들어 더욱 상세히 설명하지만, 본 발명의 권리범위가 하기 실시예로만 한정되는 것은 아니다.
Hereinafter, the structure of the present invention will be described in more detail with reference to examples, but the scope of the present invention is not limited to the following examples.
실시예Example 1: 인삼 열매 추출물의 제조(95% 에탄올 추출) 1: Preparation of Ginseng Fruit Extract (95% Ethanol Extract)
인삼 열매(전북 김제에서 재배) 100 g을 10배량의 95% 에틸알콜에 넣어 80℃에서 2 시간 동안 2회 환류 냉각시키면서 추출시킨 후, 감압 농축하고 동결 건조하여 적갈색의 인삼 열매 추출물을 얻었다.
100 g of ginseng fruit (cultivated in Jeonbuk Gimje) was added to 10 times of 95% ethyl alcohol and extracted with two reflux cooling at 80 ° C. for 2 hours, and then concentrated under reduced pressure and lyophilized to obtain a reddish brown ginseng fruit extract.
실시예Example 2: 인삼 열매 추출물의 제조(70% 에탄올 추출) 2: Preparation of Ginseng Fruit Extract (70% Ethanol Extract)
인삼 열매(전북 김제에서 재배) 100 g을 10배량의 70%인 에틸알콜에 넣어 70℃에서 2 시간 동안 2회 환류 냉각시키면서 추출시킨 후, 감압 농축하고 동결 건조하여 적갈색의 인삼 열매 추출물을 얻었다.
100 g of ginseng fruit (cultivated in Jeonbuk Gimje) was added to 10% of 70% ethyl alcohol, extracted with two reflux cooling at 70 ° C. for 2 hours, concentrated under reduced pressure, and lyophilized to obtain a reddish brown ginseng fruit extract.
실시예 3: 인삼 열매 추출물의 제조(100% 메탄올 추출)Example 3: Preparation of Ginseng Fruit Extract (100% Methanol Extract)
인삼열매 70 g 및 인삼화 30 g(모두 전북 김제에서 재배)의 혼합물을 10배량의 100% 메틸알콜에 넣어 80℃에서 2 시간 동안 2회 환류 냉각시키면서 추출시킨 후, 감압 농축하고 동결 건조하여 적갈색의 인삼 열매 추출물을 얻었다.
A mixture of 70 g of ginseng fruit and 30 g of ginseng (both grown in Jeonbuk Gimje) was extracted with 10 times of 100% methyl alcohol with two reflux cooling at 80 ° C. for 2 hours, concentrated under reduced pressure and freeze-dried to reddish brown. Ginseng fruit extract was obtained.
실시예 4: 인삼 열매 추출물의 제조(열수 추출)Example 4: Preparation of Ginseng Fruit Extract (Hot Water Extract)
인삼(전북 김제에서 재배)열매 100 g을 10배량의 증류수에 넣어 100℃에서 2 시간 동안 2회 환류 냉각시키면서 용매 추출하였다. 그 다음 추출물을 감압 농축하고 동결 건조하여 적갈색의 인삼 열매 추출물을 얻었다.
100 g of ginseng (cultivated in Jeonbuk Gimje) was added to 10 times distilled water and solvent extracted while cooling under reflux twice at 100 ° C. for 2 hours. The extract was then concentrated under reduced pressure and lyophilized to give a reddish brown ginseng fruit extract.
실험예 1: 인삼 열매 추출물의 진세노사이드 분석Experimental Example 1: Ginsenoside analysis of ginseng fruit extract
실시예 1에서 얻은 인삼 열매 추출물에 대한 진세노사이드 분석은 HPLC를 수행하였다. 진세노사이드 분석은 이미 공지된 방법을 참고로 하여 수행하였다(KO SK et al., Food Sci & Biotechnol 14: 509-513, 2005; KO SK et al., Korean J. Food Sci. Technol . 35: 536-539, 2005; Lee CR et al., Korean J. Food Sci . Technol . 36: 847-850, 2004). 순수한 진세노사이드 표준 물질(99% 순도)은 Chromadex(St. SantaAna, CA, USA.)에서 구매하여 사용하였다. HPLC 기구는 워터스 1525 바이너리 HPLC 시스템(Waters 1525 binary HPLC system, Waters, MA, U.S.A.)이고, 컬럼은 Gemini 5μC18110A(Phenomenex, 4.6x250mm, CA, USA)이었다. 이동상은 아세토니트릴(acetonitrile)(HPLCGrade, Sigma-AldrichChem Co., MO, USA) 및 증류수(HPLC grade, J.T. Baker, NJ, U.S.A.)의 혼합물이었다. 아세토니트릴 농도는 17%에서 40%(40 min), 40% 에서 60% (90 min), 60%에서 80%(95 min, stay for 105 min)로 연속적으로 증가시켰고, 마지막에는 다시 80%에서 17%(115 min, stay for 10 min)로 조절되었다. 작동 온도는 실온이었고 유속은 1.0 mL/min이었다. 크로마토그램의 용리 프로파일(elution profile)은 203 nm에서 UV/VIS 디텍터(Waters 2487 dual λabsorbance detector, MA, U.S.A.)를 이용하여 얻었다. Ginsenoside analysis of the ginseng fruit extract obtained in Example 1 was performed by HPLC. Ginsenoside analysis was performed with reference to known methods (KO SK et al., Food Sci & Biotechnol 14: 509-513, 2005; KO SK et al., Korean J. Food Sci. Technol . 35: 536-539, 2005; Lee CR et al., Korean J. Food Sci . Technol . 36: 847-850, 2004). Pure ginsenoside standard (99% purity) was purchased from Chromadex (St. Santa Ana, CA, USA.). The HPLC instrument was a Waters 1525 binary HPLC system (Waters, MA, USA) and the column was Gemini 5μC18110A (Phenomenex, 4.6 × 250 mm, CA, USA). The mobile phase was a mixture of acetonitrile (HPLCGrade, Sigma-Aldrich Chem Co., MO, USA) and distilled water (HPLC grade, JT Baker, NJ, USA). Acetonitrile concentrations increased continuously from 17% to 40% (40 min), 40% to 60% (90 min), 60% to 80% (95 min, stay for 105 min), and finally at 80% Adjusted to 17% (115 min, stay for 10 min). The operating temperature was room temperature and the flow rate was 1.0 mL / min. The elution profile of the chromatogram was obtained using a UV / VIS detector (Waters 2487 dual λabsorbance detector, MA, USA) at 203 nm.
또한, 실시예 1에서 얻은 인삼 열매 추출물(KGB) 이외에, 한국 인삼 종자 추출물(KGS, 전북 김제에서 구입), 한국 인삼 뿌리 추출물(KGR, 전북 김제에서 구입)과 미국 인삼 종자 추출물(AGS, Wausau (WI, USA))의 진세노사이드 함량도 상기 언급한 HPLC 분석법을 이용하여 분석하였고, 진세노사이드 분석 결과를 하기 표 1, 도 1 및 2에 나타내었다. 한국 인삼 종자 추출물, 한국 인삼 뿌리 추출물 및 미국 인삼 종자 추출물을 얻기 위한 추출 방법은 실시예 1에 기재된 방법을 이용하였다. 도 1, 2 및 하기 표 1에 나타난 것과 같이, 본 발명에 따른 인삼 추출물은 Re의 함량이 높음을 알 수 있다.
In addition to the ginseng fruit extract (KGB) obtained in Example 1, Korean ginseng seed extract (KGS, purchased from Jeonbuk Gimje), Korean ginseng root extract (KGR, purchased from Jeonbuk Gimje) and US ginseng seed extract (AGS, Wausau ( WI, USA)) ginsenoside content was also analyzed using the above-mentioned HPLC analysis method, the ginsenoside analysis results are shown in Table 1, Figures 1 and 2. The extraction method for obtaining Korean ginseng seed extract, Korean ginseng root extract and US ginseng seed extract was used in the method described in Example 1. As shown in Figure 1, 2 and Table 1, it can be seen that the ginseng extract according to the present invention has a high content of Re.
상기 표 1을 통해 알 수 있는 바와 같이, 본 발명에 따른 인삼 열매 추출물의 경우 진세노사이드 중 Re의 함량이 높음을 알 수 있다.
As can be seen through Table 1, the ginseng fruit extract according to the present invention can be seen that the content of Re in ginsenosides is high.
실험예Experimental Example 2: 인삼 열매 추출물이 인간 2: ginseng fruit extract is human 모유두Breast milk 세포( cell( HHDPCHHDPC ) 성장에 미치는 영향 평가) Assessment of impact on growth
실시예 1 내지 4에서 얻어진 인삼 열매 추출물이 인간 모유두세포의 세포성장에 미치는 영향을 조사하기 위하여, 모유두세포(human hair dermal papilla cell, HHDPC)(Sciencell Co., Cat. No. 2400)를 사용하여 평가하였다. In order to investigate the effect of the ginseng fruit extracts obtained in Examples 1 to 4 on cell growth of human dermal papilla cells, human hair dermal papilla cells (HHDPC) (Sciencell Co., Cat.No. 2400) were used. Evaluated.
10% 우태아의 혈청(FBS, Cambrex, USA)이 포함된 전용 배지인 MSC(Mesenchymal Stem Cell) 배지에, 모유두세포를 0.25 X 104 cells/㎖이 되도록 하고, 96-웰 플레이트에 접종하여 24 시간 동안, 37℃, 5% CO2 습윤 조건 하에서 배양하였다. In Mesenchymal Stem Cell (MSC) medium, a dedicated medium containing 10% fetal calf serum (FBS, Cambrex, USA), make the dermal papilla cells 0.25 x 10 4 cells / ml and inoculate 96-well plates. For hours, incubated under 37 ° C., 5% CO 2 wet conditions.
상기 배양액에 실시예 1 내지 4에서 얻어진 인삼 열매 추출물을 각각 0.4, 20, 100, 500 ug/ml의 농도로 처리하여 24, 48, 72 시간 동안 배양한 후, 5 mg/㎖의 MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide)시약 20 ㎕를 상기 배양액에 넣고 3℃, 5% CO2 습윤 조건하에서 4 시간 동안 배양하였다. 대조군으로는 인삼 열매 추출물을 처리하지 않은 세포를 배양한 것을 사용하였다.The culture solution of the ginseng fruit extract obtained in Examples 1 to 4 at concentrations of 0.4, 20, 100, and 500 ug / ml, respectively, was cultured for 24, 48 and 72 hours, and then 5 mg / ml of MTT (3- 20 [mu] l of (4,5-dimethylthiazol-2-yl) -2,5-diphenyl tetrazolium bromide) reagent was added to the culture solution and incubated for 4 hours under 3 ° C and 5% CO 2 wet conditions. As a control, a culture of cells not treated with ginseng fruit extract was used.
배양 시, 살아있는 세포에는 보라색의 크리스탈이 형성된다. 4 시간 배양 후 배지를 제거하고 DMSO 100 ㎕를 넣어 10분 동안 쉐이킹 인큐베이터(shaking incubator)에서 크리스탈을 녹인 후 540 nm에서 흡광도를 측정하여 세포 성장의 정도를 측정하였다. 그 결과를 도 3에 나타냈다. 도 3을 통해, 인삼 열매 추출물이 모유두 세포의 성장을 촉진함을 알 수 있다. In culture, purple crystals form on living cells. After incubation for 4 hours, the medium was removed, 100 μl of DMSO was added, the crystals were dissolved in a shaking incubator for 10 minutes, and the absorbance was measured at 540 nm to measure the extent of cell growth. The result is shown in FIG. 3, it can be seen that ginseng fruit extract promotes the growth of dermal papilla cells.
상기 인삼 열매 추출물을 인간모유두 세포(Human Hair Dermal Papilla Cell)에 0.4-500 ug/ml로 처리했을 때 모든 농도에서 유의적인 세포독성이 나타나지 않았다. 상기 인삼 열매 추출물은 농도의존적으로 인간모유두 세포를 대조군 대비 121%에서 135%까지 세포증식을 촉진하는 것으로 나타났다. When the ginseng fruit extract was treated with 0.4-500 ug / ml of Human Hair Dermal Papilla Cell, there was no significant cytotoxicity at all concentrations. The ginseng fruit extract was found to promote cell growth from 121% to 135% of human dermal papilla cells in a concentration-dependent manner.
따라서 이와 같은 인삼열매 추출물의 모유두세포 증식에 근거하여 인삼 열매 추출물은 탈모 방지 및 모발 성장 촉진효과를 나타내는 것으로 생각된다.
Therefore, based on the growth of the dermal papilla cells of the ginseng berry extract, the ginseng fruit extract is thought to exhibit hair growth prevention and hair growth promoting effect.
실험예 3: 인삼 열매 추출물에 의한 C57BL/6 마우스에서의 모발 생장 효과Experimental Example 3: Hair Growth Effect in C57BL / 6 Mice by Ginseng Fruit Extract
인삼 열매 추출물에 의한 C57BL/6 마우스에서의 모발 생장 효과를 측정하기 위해, 7 주령의 C57BL/6 마우스를 마취시킨 후 왁싱 레진을 사용하여 등 부위 털을 모낭세포로부터 완전히 제거하였다. 그 다음, 등 부위의 털을 제거한 마우스를 10마리씩 4개의 군으로 나누었다. 도 4에 나타낸 바와 같이, 등 부위의 털을 전기제모기로 제거하고 아무런 처리를 하지 않은 군(normal)을 별도로 준비하였다. A군은 대조군으로서, 70% 에탄올을 매일 1회씩 도포하였고 총 21일 동안 변화를 관찰하였다. B 군은 미녹시딜을 21일 동안 하루에 한번씩 도포하였다. C 및 D군은 실시예 1에서 얻은 인삼 열매 추출물을 50% 에탄올에 녹여 각각 1 mg/마리 및 10 mg/마리의 용량으로 마우스 등 피부에 매일 1회씩 21일 동안 도포하였고, 총 21일간 변화를 관찰하였다. 이러한 처치를 한 후, 21일까지 마우스의 변화를 관찰하여 도 4에 나타내었다.To measure the hair growth effect in C57BL / 6 mice by ginseng fruit extract, After 7 weeks of age C57BL / 6 mice were anesthetized, the back hair was completely removed from the hair follicle cells using waxing resin. Then, the mice with the back hair removed were divided into four groups of 10 mice each. As shown in Figure 4, the hair on the back portion was removed with an electric hair remover and no treatment (normal) was prepared separately. Group A was applied as a control, 70% ethanol once daily and observed changes for a total of 21 days. Group B applied minoxidil once daily for 21 days. Group C and D were dissolved in 50% ethanol in the ginseng fruit extract obtained in Example 1 and applied to the skin such as mice once daily for 21 days at doses of 1 mg / ml and 10 mg / ml, respectively, for a total of 21 days Observed. After these treatments, changes in the mice were observed until
또한 피부 내 모낭(hair follicle)의 변화, 피부 두께 및 조직의 변화를 관찰하기 위하여, 14일 및 21일에 각 군의 마우스 중 한 마리를 치사시킨 후, 등 쪽 피부의 발모된 부위의 조직을 채취하여 4% 포름알데히드 용액으로 고정하였다. 고정 후, 수세 및 탈수 과정을 거쳐 파라핀(paraffin)으로 포매(embedding)하고, 7 ㎛의 절편을 제작하여 H&E(Hematoxylin & Eosin)염색을 시행하였으며, 육안적 변화 및 조직학적 변화를 도 5에 나타냈다. In addition, in order to observe changes in hair follicle, skin thickness, and tissue in the skin, one of the mice in each group was killed on the 14th and 21st days, and then the tissue of the hair growth site of the dorsal skin was removed. Extracted and fixed with 4% formaldehyde solution. After fixation, the cells were embedded with paraffin through washing and dehydration, and 7 μm sections were prepared and stained with H & E (Hematoxylin & Eosin). The visual and histological changes are shown in FIG. 5. .
도 4를 통해, 인삼 열매 추출물을 처리한 마우스의 등(C 및 D군)이 인삼 열매 추출물을 처리하지 않은 군에 비하여 피부색이 단시간에 검게 변하며 털이 빨리 자랐음을 확인할 수 있다.4, the back of the mouse treated with ginseng fruit extract (C and D group) compared to the group not treated with the ginseng fruit extract can be confirmed that the skin color is black in a short time and the hair grew quickly.
도 5을 통해 실제 피부조직에서도, 인삼 열매 추출물 처리군(C 및 D군)의 경우 대조군에 비해 모낭의 수가 낮은 농도(100 ug/마리)에서는 14일째 음성대조군 대비 300%, 높은 농도(10 mg/마리)에서는 188%의 증가율을 보였고, 21일째에는 음성대조군 대비 123%, 높은 농도(10 mg/마리)에서는 108%(16/26개)의 증가율을 보였다. 이때, 양성 대조군의 경우 각각 325%, 123%의 증가율을 나타냈다. 특히, 높은 농도군에서는 모낭의 수보다도 모낭의 형태적 변화가 나타나 모주기가 촉진되고 있음이 관찰되었다. In Figure 5 through the actual skin tissue, ginseng fruit extract treatment group (C and D group) in the low concentration (100 ug / horse) of the number of hair follicles compared to the
도 6은, 인삼열매 추출물 도포 21일 후 C 군의 마우스의 등쪽 1 cm x 3 cm 부위의 피부 조직을 취한 후 새로 성장된 모발의 중량을 측정하여, 대조군(A 및 B)과 비교한 결과를 나타낸 것이다. 도 6을 통해, 인삼 열매 추출물을 처리한 군의 경우, 음성 대조군과 비교하여 발모 효과가 우수함을 확인할 수 있다.Figure 6, after taking
따라서 본 발명에 따른 인삼 열매 추출물이 피부자극이 없는 안전한 물질로 구성되어 있으며, 탈모 방지 및 모발 성장 촉진할 수 있음을 알 수 있다.
Therefore, ginseng fruit extract according to the present invention is composed of a safe substance without skin irritation, it can be seen that it can prevent hair loss and promote hair growth.
제조예 1: 인삼 열매 추출물을 포함하는 피부 외용제 제조Preparation Example 1: Preparation of external preparation for skin containing ginseng fruit extract
1-1: 인삼 열매 추출물을 함유한 마사지크림1-1: Massage Cream with Ginseng Fruit Extract
본 발명의 인삼 열매 추출물을 함유한 마사지크림의 제조예는 하기 표 2에 나타낸 바와 같다. 수상인 정제수, 트리에탄올아민, 글리콜(1,3-Propanediol)을 70℃로 가열하고 용해시키고, 여기에 유상인 지방산, 유성성분, 유화제 및 방부제를 70℃로 가열하여 용해한 액을 첨가하여 유화시킨다. 유화가 완료된 후 상기 용액을 45℃로 냉각시키고 인삼 열매 추출물과 향을 첨가하고 분산시킨 다음 30℃로 냉각한다.
The preparation example of the massage cream containing the ginseng fruit extract of the present invention is as shown in Table 2 below. The aqueous phase purified water, triethanolamine and glycol (1,3-Propanediol) are heated and dissolved at 70 ° C., and the oily fatty acid, oily component, emulsifier and preservative are heated to 70 ° C. and dissolved to add the emulsified product. After emulsification is completed, the solution is cooled to 45 ° C., the ginseng fruit extract and flavor are added and dispersed, and then cooled to 30 ° C.
1-2: 인삼 열매 추출물을 함유한 정제1-2: Tablets containing Ginseng Fruit Extract
인삼 열매 추출물을 함유한 정제의 제조예는 하기 표 3에 나타낸 바와 같다.
Preparation of tablets containing ginseng fruit extract is shown in Table 3 below.
본 발명의 단순한 변형 내지 변경은 이 분야의 통상의 지식을 가진 자에 의하여 용이하게 실시될 수 있으며, 이러한 변형이나 변경은 모두 본 발명의 영역에 포함되는 것으로 볼 수 있다.
Simple modifications or changes of the present invention can be easily carried out by those skilled in the art, and all such modifications or changes can be seen to be included in the scope of the present invention.
Claims (8)
Contains ginseng fruit extract as an active ingredient, hair loss prevention and hair growth promoting composition.
The composition for preventing hair loss and promoting hair growth according to claim 1, wherein the ginseng fruit extract comprises 1 to 70% by weight of ginsenoside Re based on the total ginsenoside weight in the ginseng fruit extract.
According to claim 1, The ginseng fruit extract is characterized in that the extract is extracted from one or more selected from the group consisting of ginseng fruit, ginseng, ginseng stem and ginseng leaves, hair loss prevention and hair growth promoting composition.
According to claim 1, wherein the ginseng fruit extract, characterized in that it has a growth promoting activity of human dermal papilla cells, hair loss prevention and hair growth promoting composition.
The method of claim 1, wherein the extract is any solvent selected from the group consisting of water, C 1 -C 4 alcohol, n-hexane, ethyl acetate and a mixed solvent thereof, 0.5 to 4 at 40 to 120 ℃ A composition for preventing hair loss and promoting hair growth, which is obtained by heating for a time.
The pharmaceutical composition of claim 1, wherein the composition is formulated in one form selected from the group consisting of powders, granules, tablets, capsules, suspensions, emulsions, syrups, oral formulations of aerosols, external preparations and sterile injectable solutions. A composition for preventing hair loss and promoting hair growth, characterized in that the composition.
The composition for preventing hair loss and promoting hair growth according to claim 1, wherein the composition is a cosmetic composition having a formulation selected from the group consisting of massage creams, hair essences, hair dyes, shampoos and rinses.
According to claim 1, The ginseng fruit extract is characterized in that it comprises 0.001 to 50% by weight based on the total weight of the composition, hair loss prevention and hair growth promoting composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100065809A KR101221417B1 (en) | 2010-07-08 | 2010-07-08 | Composition including ginseng berry extract for promoting hair growth |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100065809A KR101221417B1 (en) | 2010-07-08 | 2010-07-08 | Composition including ginseng berry extract for promoting hair growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20120005195A true KR20120005195A (en) | 2012-01-16 |
| KR101221417B1 KR101221417B1 (en) | 2013-01-11 |
Family
ID=45611427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020100065809A Active KR101221417B1 (en) | 2010-07-08 | 2010-07-08 | Composition including ginseng berry extract for promoting hair growth |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101221417B1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130095949A (en) * | 2012-02-21 | 2013-08-29 | (주)아모레퍼시픽 | Composition of skin external application containing ginsenoside f1 |
| WO2014175675A1 (en) * | 2013-04-24 | 2014-10-30 | 주식회사 아모레퍼시픽 | Topical composition for skin containing gincenoside mc |
| WO2015002391A1 (en) * | 2013-07-04 | 2015-01-08 | (주)아모레퍼시픽 | Composition having a function for alleviating premenstrual syndrome and menstrual pain |
| WO2015005700A1 (en) * | 2013-07-11 | 2015-01-15 | (주)아모레퍼시픽 | Composition for promoting hair sprouting and hair growth |
| WO2015005554A1 (en) * | 2013-07-11 | 2015-01-15 | (주)아모레퍼시픽 | Composition for promoting hair sprouting and hair growth |
| US20150283192A1 (en) * | 2014-04-07 | 2015-10-08 | Gangneung-Wonju National University Industry Academy Cooperation Group | Composition and method for enhancing alcohol metabolism |
| WO2017135637A1 (en) * | 2016-02-02 | 2017-08-10 | (주)아모레퍼시픽 | Composition for promoting hair growth or for preventing hair loss, comprising extract of flower stalk of ginseng |
| WO2018026103A1 (en) * | 2016-07-14 | 2018-02-08 | (주)아모레퍼시픽 | Composition for cell regeneration comprising ginseng floral axis extract |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250042284A (en) | 2023-09-20 | 2025-03-27 | 박경원 | Method for promoting transplanted hair engraftment and growth using hair root stem cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101550917B1 (en) * | 2008-06-16 | 2015-09-08 | (주)아모레퍼시픽 | An external composition for skin containing ginseng seed extract |
| KR20090129928A (en) * | 2008-06-13 | 2009-12-17 | (주)아모레퍼시픽 | Skin external composition containing ginseng flower extract |
| KR20100062094A (en) * | 2008-12-01 | 2010-06-10 | 김신정 | A composition for preventing and treating allergy comprising the extract of ginseng berry, ginseng flower and ginseng stem |
-
2010
- 2010-07-08 KR KR1020100065809A patent/KR101221417B1/en active Active
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130095949A (en) * | 2012-02-21 | 2013-08-29 | (주)아모레퍼시픽 | Composition of skin external application containing ginsenoside f1 |
| WO2014175675A1 (en) * | 2013-04-24 | 2014-10-30 | 주식회사 아모레퍼시픽 | Topical composition for skin containing gincenoside mc |
| US10342836B2 (en) | 2013-07-04 | 2019-07-09 | Amorepacific Corporation | Composition having a function for alleviating premenstrual syndrome and menstrual pain |
| WO2015002391A1 (en) * | 2013-07-04 | 2015-01-08 | (주)아모레퍼시픽 | Composition having a function for alleviating premenstrual syndrome and menstrual pain |
| WO2015005700A1 (en) * | 2013-07-11 | 2015-01-15 | (주)아모레퍼시픽 | Composition for promoting hair sprouting and hair growth |
| WO2015005554A1 (en) * | 2013-07-11 | 2015-01-15 | (주)아모레퍼시픽 | Composition for promoting hair sprouting and hair growth |
| KR20150007975A (en) * | 2013-07-11 | 2015-01-21 | (주)아모레퍼시픽 | Composition for promoting hair growth and restoration |
| JP2016523957A (en) * | 2013-07-11 | 2016-08-12 | 株式会社アモーレパシフィックAmorepacific Corporation | Composition for promoting hair growth and hair growth |
| US20150283192A1 (en) * | 2014-04-07 | 2015-10-08 | Gangneung-Wonju National University Industry Academy Cooperation Group | Composition and method for enhancing alcohol metabolism |
| US9901608B2 (en) * | 2014-04-07 | 2018-02-27 | Gangneung-Wonju National University Industry Academy Cooperation Group | Composition and method for enhancing alcohol metabolism |
| WO2017135637A1 (en) * | 2016-02-02 | 2017-08-10 | (주)아모레퍼시픽 | Composition for promoting hair growth or for preventing hair loss, comprising extract of flower stalk of ginseng |
| WO2018026103A1 (en) * | 2016-07-14 | 2018-02-08 | (주)아모레퍼시픽 | Composition for cell regeneration comprising ginseng floral axis extract |
| CN109475168A (en) * | 2016-07-14 | 2019-03-15 | 株式会社爱茉莉太平洋 | Composition for cell regeneration comprising ginseng flower shaft extract |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101221417B1 (en) | 2013-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101221417B1 (en) | Composition including ginseng berry extract for promoting hair growth | |
| CN106214592B (en) | Hair follicle nutrient liquor composition and preparation method thereof | |
| KR101059471B1 (en) | Cosmetic composition for skin aging | |
| KR101017709B1 (en) | Cosmetic composition having the effect of preventing hair loss, inhibiting dandruff, and promoting hair growth containing complex herbal extracts such as ginseng | |
| KR101132246B1 (en) | The hair growth solution mainly comprised of ginsenoside rg3 and rh2, and the hair treatment composition | |
| KR101434717B1 (en) | Composition for preventing hair loss or promoting hair growth comprising extracts of Panax ginseng and Hijikia fusiforme | |
| KR101686008B1 (en) | Composition comprising extract of herbal mixture for preventing alopecia or hair growth effect | |
| KR20140020005A (en) | Cistanche tubulosa, fucoidan extract for promoting hair growth and preventing hair loss & manufacturing method thereof | |
| KR101757775B1 (en) | Composition for prevention or treatment of hair loss comprising extracts of oriental melon leaves | |
| JP6709783B2 (en) | Composition for preventing hair loss or promoting hair growth containing alpine wormwood extract | |
| KR20140092087A (en) | Composition for preventing hair loss or promoting hair growth comprising an extract of Flos Sophora japonica Linne | |
| KR20090076671A (en) | Process for producing hair loss prevention and hair growth promoting composition | |
| KR101484033B1 (en) | Composition for preventing hair loss or promoting hair growth comprising an extract of shell Arachis hypogaea Linne | |
| KR20160081204A (en) | Composition for improving hair and scalp condition coprising extract of hydrangea serrata | |
| KR20140131243A (en) | Composition for preventing hair loss or promoting hair growth comprising Ginsenoside F2 | |
| KR100664400B1 (en) | Hair Loss Prevention and Wool Composition | |
| KR20210058772A (en) | Composition for treating hair loss and promoting hair growth | |
| KR20210104608A (en) | Composition for preventing hair loss or promoting hair growth comprising extract pupae of male bees | |
| KR20130036984A (en) | Cosmetic composition for inhibiting hair loss and enhanching hair growth | |
| JP7100351B2 (en) | CXCL12 expression promoter | |
| KR101740970B1 (en) | Topical composition comprising the herbal mixed extract including phytoncide of Chamaecyparis obtusa showing hair-growth stimulating activity and preventing effect on hair loss | |
| KR102557372B1 (en) | Composition for Preventing or Treating Hair Loss or Stimulating Hair Sprouting or Hair Growth Comprising Extracts of Rosa davurica Pall as Active Ingredient | |
| TW201618803A (en) | Composition for preventing hair loss or accelerating hair growth comprising scutellaria alpina extract | |
| KR20140114709A (en) | Composition for Improving Skin Conditions Comprising Boehmeria spicata (Thunb.) Thunb Extract | |
| KR20100007003A (en) | Composition for preventing hair loss or promoting hair growth comprising an extract of crataegis fructus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20100708 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20120607 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20121211 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20130107 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20130108 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20161223 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20161223 Start annual number: 5 End annual number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20180104 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180104 Start annual number: 6 End annual number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20181217 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20181217 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20191223 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20191223 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20201210 Start annual number: 9 End annual number: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20231226 Start annual number: 12 End annual number: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20241231 Start annual number: 13 End annual number: 13 |